[Atrial fibrillation: where is the border between pure antiarrhythmic and non-antiarrhythmic medicines?].
The author discusses the modern approaches to the treatment of atrial fibrillation including the use of omega-3 polyunsaturated fatty acids that have antiarrhythmic properties and have favorable effect on arrhythmia substrate.
S V
SV
Moiseev
D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology; D001682:Biological Availability; D002986:Clinical Trials as Topic; D015525:Fatty Acids, Omega-3 / Q000493:pharmacokinetics / Q000627:therapeutic use; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D011379:Prognosis; D015996:Survival Rate
D000889:Anti-Arrhythmia Agents; D015525:Fatty Acids, Omega-3